View Author
stent patient lesion vessel study trial group angiographic artery revascularization follow-up diameter restenosi target difference month infarction death outcome sxscore sirolimus-eluting event table score randomized syntax score in-stent everolimus-eluting intervention value result procedure artery disease sirolimus-eluting stents syntax analysis disease thrombosis stent thrombosis percutaneou everolimus-eluting stent serruy signi failure point stenosi signi ficantly treatment end point implantation spirit 1.00 cardiol circulation characteristic complexity endpoint comer comers trial cardiology drug-eluting newer-generation des zotarolimus-eluting strati vessel diameter in-segment finite sirolimus-eluting stent group restenosis rate 1 year population sirolimus-eluting stent spirit ii hospital comparison everolimus-stent group zotarolimus-eluting stent vessel size lumen angiography
6 Most Recent Publications
|
The impact of patient and lesion complexity on clinical and angiographic outcomes after revascularization with zotarolimus- and everolimus-eluting stents: A substudy of the RESOLUTE all comers trial (a randomized comparison of a zotarolimus-eluting stent with an everolimus-eluting stent for percutaneous coronary intervention)
(Article)
Stefanini, G.G. Serruys, P.W.J.C. Linke, A. Klauss, V. Wijns, W. Macaya, C. Garot, P. Mario, C. di Manoharan, G. Kornowski, R. Ischinger, T. Bartorelli, A. Silber, S. Gobbens, P. Windecker, S. Khattab, A.A. Geuns, R-J.M. van Richardt, G. Buszman, P. Kelbæk, H. Boven, A.J. van Hofma, S.H. |
2011-05-31
|
|
The prognostic utility of the SYNTAX score on 1-year outcomes after revascularization with zotarolimus- and everolimus-eluting stents: A substudy of the resolute all comers trial
(Article)
Garg, S.A. Serruys, P.W.J.C. Linke, A. Klauss, V. Wijns, W. Macaya, C. Garot, P. Mario, C. di Manoharan, G. Kornowski, R. Ischinger, T. Bartorelli, A. Silber, S. Remortel, E. van Ronden, J. Windecker, S. Wykrzykowska, J.J. Geuns, R-J.M. van Richardt, G. Buszman, P. Kelbæk, H. Boven, A.J. van Hofma, S.H. |
2011-04-01
|
|
Comparison of zotarolimus-eluting and everolimus-eluting coronary stents
(Article)
Serruys, P.W.J.C. Silber, S. Klauss, V. Wijns, W. Macaya Miguel, C.M. Garot, P. DiMario, C. Manoharan, G. Kornowski, R. Ischinger, T. Bartorelli, A. Ronden, J. Garg, S.A. Geuns, R-J.M. van Richardt, G. Buszman, P. Kelbaek, H. Boven, A.J. Hofma, S.H. Linke, A. |
2010-07-01
|
|
An everolimus-eluting stent versus a paclitaxel-eluting stent in small vessel coronary artery disease: A pooled analysis from the SPIRIT II and SPIRIT III trials
(Article)
Bartorelli, A. Serruys, P.W.J.C. Miquel, K. Yu, S. Pierson, W. Stone, G.W. |
2010-07-01
|
|
Maintenance of long-term clinical benefit with sirolimus-eluting coronary stents: three-year results of the RAVEL trial.
(Article)
Fajadet, J. Morice, M-C. Laarman, G-J. Perin, M.A. Sousa, J.E. Schuler, G. Molnar, F. Guagliumi, G. Colombo, A. Ban Hayashi, E. Wülfert, E. Barragan, P. Serruys, P.W.J.C. Wijns, W. Constantini, C. Guermonprez, J-L. Eltchaninoff, H. Blanchard, D. Bartorelli, A. |
2005-03-01
|
|
Angiographic Findings of the Multicenter Randomized Study With the Sirolimus-Eluting Bx Velocity Balloon-Expandable Stent (RAVEL)
(Article)
Regar, E.S. Degertekin, M. Serruys, P.W.J.C. Bode, C. Constantini, C. Morice, M-C. Tanabe, K. Wülfert, E. Disco, C. Holubarsch, C. Guermonprez, J-L. Wijns, W. Bartorelli, A. |
2002-10-08
|
